Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Neuropsychopharmacology ; 42(11): 2222-2231, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28272498

ABSTRACT

Cannabis use increases rates of psychotic relapse and treatment failure in schizophrenia patients. Clinical studies suggest that cannabis use reduces the efficacy of antipsychotic drugs, but there has been no direct demonstration of this in a controlled study. The present study demonstrates that exposure to the principal phytocannabinoid, Δ9-tetrahydrocannabinol (THC), reverses the neurobehavioral effects of the antipsychotic drug risperidone in mice. THC exposure did not influence D2 and 5-HT2A receptor binding, the major targets of antipsychotic action, but it lowered the brain concentrations of risperidone and its active metabolite, 9-hydroxy risperidone. As risperidone and its active metabolite are excellent substrates of the ABC transporter P-glycoprotein (P-gp), we hypothesized that THC might increase P-gp expression at the blood-brain barrier (BBB) and thus enhance efflux of risperidone and its metabolite from brain tissue. We confirmed that the brain disposition of risperidone and 9-hydroxy risperidone is strongly influenced by P-gp, as P-gp knockout mice displayed greater brain concentrations of these drugs than wild-type mice. Furthermore, we demonstrated that THC exposure increased P-gp expression in various brain regions important to risperidone's antipsychotic action. We then showed that THC exposure did not influence the neurobehavioral effects of clozapine. Clozapine shares a very similar antipsychotic mode of action to risperidone, but unlike risperidone is not a P-gp substrate. Our results imply that clozapine or non-P-gp substrate antipsychotic drugs may be better first-line treatments for schizophrenia patients with a history of cannabis use.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Antipsychotic Agents/pharmacology , Brain/metabolism , Gene Expression Regulation/drug effects , ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , Animals , Brain/drug effects , Clozapine/pharmacology , Dose-Response Relationship, Drug , Dronabinol/pharmacology , Gene Expression Regulation/genetics , Locomotion/drug effects , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Protein Binding/drug effects , Proto-Oncogene Proteins c-fos/metabolism , Raclopride/pharmacokinetics , Receptor, Serotonin, 5-HT2A/metabolism , Receptors, Dopamine D2/metabolism , Reflex, Startle/drug effects , Risperidone/pharmacology , Time Factors , Tritium/pharmacokinetics
2.
Schizophr Bull ; 40(6): 1272-84, 2014 Nov.
Article in English | MEDLINE | ID: mdl-24442851

ABSTRACT

Stress has been linked to the pathogenesis of schizophrenia. Genetic variation in neuregulin 1 (NRG1) increases the risk of developing schizophrenia and may help predict which high-risk individuals will transition to psychosis. NRG1 also modulates sensorimotor gating, a schizophrenia endophenotype. We used an animal model to demonstrate that partial genetic deletion of Nrg1 interacts with stress to promote neurobehavioral deficits of relevance to schizophrenia. Nrg1 heterozygous (HET) mice displayed greater acute stress-induced anxiety-related behavior than wild-type (WT) mice. Repeated stress in adolescence disrupted the normal development of higher prepulse inhibition of startle selectively in Nrg1 HET mice but not in WT mice. Further, repeated stress increased dendritic spine density in pyramidal neurons of the medial prefrontal cortex (mPFC) selectively in Nrg1 HET mice. Partial genetic deletion of Nrg1 also modulated the adaptive response of the hypothalamic-pituitary-adrenal axis to repeated stress, with Nrg1 HET displaying a reduced repeated stress-induced level of plasma corticosterone than WT mice. Our results demonstrate that Nrg1 confers vulnerability to repeated stress-induced sensorimotor gating deficits, dendritic spine growth in the mPFC, and an abberant endocrine response in adolescence.


Subject(s)
Dendritic Spines , Hypothalamo-Hypophyseal System/physiopathology , Neuregulin-1/physiology , Pituitary-Adrenal System/physiopathology , Prefrontal Cortex/cytology , Sensory Gating/physiology , Stress, Psychological/physiopathology , Animals , Disease Models, Animal , Female , Male , Mice , Mice, Inbred C57BL , Neuregulin-1/genetics , Prepulse Inhibition/physiology
3.
Front Cell Neurosci ; 7: 15, 2013.
Article in English | MEDLINE | ID: mdl-23447498

ABSTRACT

Neuregulin 1 (NRG1) is linked to an increased risk of developing schizophrenia and cannabis dependence. Mice that are hypomorphic for Nrg1 (Nrg1 HET mice) display schizophrenia-relevant behavioral phenotypes and aberrant expression of serotonin and glutamate receptors. Nrg1 HET mice also display idiosyncratic responses to the main psychoactive constituent of cannabis, Δ(9)-tetrahydrocannabinol (THC). To gain traction on the molecular pathways disrupted by Nrg1 hypomorphism and Nrg1-cannabinoid interactions we conducted a proteomic study. Adolescent wildtype (WT) and Nrg1 HET mice were exposed to repeated injections of vehicle or THC and their hippocampi were submitted to 2D gel proteomics. Comparison of WT and Nrg1 HET mice identified proteins linked to molecular changes in schizophrenia that have not been previously associated with Nrg1. These proteins are involved in vesicular release of neurotransmitters such as SNARE proteins; enzymes impacting serotonergic neurotransmission, and proteins affecting growth factor expression. Nrg1 HET mice treated with THC expressed a distinct protein expression signature compared to WT mice. Replicating prior findings, THC caused proteomic changes in WT mice suggestive of greater oxidative stress and neurodegeneration. We have previously observed that THC selectively increased hippocampal NMDA receptor binding of adolescent Nrg1 HET mice. Here we observed outcomes consistent with heightened NMDA-mediated glutamatergic neurotransmission. This included differential expression of proteins involved in NMDA receptor trafficking to the synaptic membrane; lipid raft stabilization of synaptic NMDA receptors; and homeostatic responses to dampen excitotoxicity. These findings uncover novel proteins altered in response to Nrg1 hypomorphism and Nrg1-cannabinoid interactions that improves our molecular understanding of Nrg1 signaling and Nrg1-mediated genetic vulnerability to the neurobehavioral effects of cannabinoids.

4.
Prog Neuropsychopharmacol Biol Psychiatry ; 39(2): 376-81, 2012 Dec 03.
Article in English | MEDLINE | ID: mdl-22850204

ABSTRACT

Methamphetamine use triggers psychosis in genetically vulnerable individuals, however the exact nature of this genetic predisposition requires elucidation. In addition, adolescence may be a particular period of neurodevelopmental vulnerability to the actions of methamphetamine; interestingly, this period coincides with a higher likelihood of onset of schizophrenia and drug experimentation. In the current study we investigated whether adolescent mice heterozygous for the schizophrenia susceptibility gene neuregulin 1 (Nrg1 HET mice) exhibit altered behavioural responses to methamphetamine (0.6 or 2.4mg/kg) in schizophrenia-relevant paradigms. The responses measured were locomotor activity in the open field test and sensorimotor gating function in the prepulse inhibition of startle paradigm (PPI). Adolescent Nrg1 HET mice displayed a subtle, transient, novelty-induced baseline locomotor hyperactivity over days, and a selective PPI deficit at the prepulse intensity-interstimulus interval (ISI) combination of 82dB-64ms. Adolescent Nrg1 HET mice were more sensitive to the locomotor stimulatory effects of an acute, low-dose of methamphetamine (0.6mg/kg) relative to wild-type (WT) controls. The augmented response to acute methamphetamine observed in Nrg1 HET mice disappeared with repeated, daily dosing over 7days. Methamphetamine did not affect average PPI (total or across different prepulse intensities), however 0.6mg/kg methamphetamine triggered a PPI deficit selectively in Nrg1 HET mice but not WT mice at 82dB-256ms. Our results show that locomotor hyperactivity in Nrg1 HET mice, albeit subtle, can manifest much earlier than previously reported and that Nrg1 may confer vulnerability to the acute actions of methamphetamine, a drug known to trigger psychotic reactions in humans.


Subject(s)
Heterozygote , Methamphetamine/pharmacology , Neuregulin-1/genetics , Age Factors , Animals , Dose-Response Relationship, Drug , Drug Administration Schedule , Male , Methamphetamine/administration & dosage , Mice , Mice, Inbred C57BL , Motor Activity/drug effects , Sensory Gating/drug effects
5.
PLoS One ; 7(4): e35937, 2012.
Article in English | MEDLINE | ID: mdl-22536451

ABSTRACT

The ABC transporters P-glycoprotein (P-gp, Abcb1) and breast cancer resistance protein (Bcrp, Abcg2) regulate the CNS disposition of many drugs. The main psychoactive constituent of cannabis Δ(9)-tetrahydrocannabinol (THC) has affinity for P-gp and Bcrp, however it is unknown whether these transporters modulate the brain accumulation of THC and its functional effects on the CNS. Here we aim to show that mice devoid of Abcb1 and Abcg2 retain higher brain THC levels and are more sensitive to cannabinoid-induced hypothermia than wild-type (WT) mice. Abcb1a/b (-/-), Abcg2 (-/-) and wild-type (WT) mice were injected with THC before brain and blood were collected and THC concentrations determined. Another cohort of mice was examined for THC-induced hypothermia by measuring rectal body temperature. Brain THC concentrations were higher in both Abcb1a/b (-/-) and Abcg2 (-/-) mice than WT mice. ABC transporter knockout mice exhibited delayed elimination of THC from the brain with the effect being more prominent in Abcg2 (-/-) mice. ABC transporter knockout mice were more sensitive to THC-induced hypothermia compared to WT mice. These results show P-gp and Bcrp prolong the brain disposition and hypothermic effects of THC and offer a novel mechanism for both genetic vulnerability to the psychoactive effects of cannabis and drug interactions between CNS therapies and cannabis.


Subject(s)
ATP-Binding Cassette Transporters/genetics , Brain/metabolism , Dronabinol/pharmacokinetics , Psychotropic Drugs/pharmacokinetics , ATP Binding Cassette Transporter, Subfamily B , ATP Binding Cassette Transporter, Subfamily B, Member 1/deficiency , ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , ATP Binding Cassette Transporter, Subfamily G, Member 2 , ATP-Binding Cassette Transporters/metabolism , Animals , Brain/drug effects , Dronabinol/pharmacology , Female , Hypothermia/chemically induced , Mice , Mice, Knockout , Psychotropic Drugs/pharmacology
6.
Int J Neuropsychopharmacol ; 14(5): 631-43, 2011 Jun.
Article in English | MEDLINE | ID: mdl-20701826

ABSTRACT

Cannabis increases the risk of schizophrenia in genetically vulnerable individuals. In this study we aim to show that the schizophrenia susceptibility gene neuregulin 1 (Nrg1) modulates the development of tolerance to cannabinoids in mice. Nrg1 heterozygous (HET) and wild-type (WT) mice were treated daily for 15 d with the synthetic analogue of Δ9-tetrahydrocannabinol, CP55,940 (0.4 mg/kg). We measured the impact of this exposure on locomotor activity, anxiety, prepulse inhibition (PPI), body temperature and FosB/ΔFosB immunohistochemistry. Tolerance to CP55,940-induced hypothermia and locomotor suppression developed more rapidly in Nrg1 HET mice than WT mice. Conversely in the light-dark test, while tolerance to the anxiogenic effect of CP55,940 developed in WT mice over days of testing, Nrg1 hypomorphs maintained marked anxiety even after 15 d of treatment. Repeated cannabinoid exposure selectively increased FosB/ΔFosB expression in the lateral septum, ventral part (LSV) of Nrg1 HET but not WT mice. On day 1 of exposure opposite effects of CP55,940 treatment were observed on PPI, i.e. it was facilitated in Nrg1 hypomorphs and impaired in WT mice, despite the drug significantly impairing the acoustic startle reflex equally in both genotypes. These effects of CP55,940 on PPI were not maintained as both genotypes became tolerant to cannabinoid action with repeated exposure. Our results highlight that Nrg1 modulates the development of cannabinoid tolerance dependent on the parameter being measured. Furthermore, these data reinforce the notion that the VLS is an important brain region involved in Nrg1-cannabinoid interactions.


Subject(s)
Cannabinoids/pharmacology , Drug Tolerance/genetics , Neuregulin-1/physiology , Psychotropic Drugs/pharmacology , Schizophrenia/genetics , Animals , Anxiety/drug therapy , Anxiety/genetics , Behavior, Animal/drug effects , Behavior, Animal/physiology , Brain/drug effects , Cannabinoids/genetics , Cyclohexanols/pharmacology , Disease Models, Animal , Dronabinol/analogs & derivatives , Exploratory Behavior/drug effects , Exploratory Behavior/physiology , Genotype , Heterozygote , Male , Mice , Mice, Mutant Strains , Motor Activity/drug effects , Motor Activity/genetics , Neuregulin-1/genetics , Proto-Oncogene Proteins c-fos/drug effects , Proto-Oncogene Proteins c-fos/physiology , Reflex, Startle/drug effects , Reflex, Startle/genetics
7.
Schizophr Res ; 124(1-3): e1-62, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20934307

ABSTRACT

The 2nd Schizophrenia International Research Society Conference, was held in Florence, Italy, April 10-15, 2010. Student travel awardees served as rapporteurs of each oral session and focused their summaries on the most significant findings that emerged from each session and the discussions that followed. The following report is a composite of these reviews. It is hoped that it will provide an overview for those who were present, but could not participate in all sessions, and those who did not have the opportunity to attend, but who would be interested in an update on current investigations ongoing in the field of schizophrenia research.


Subject(s)
Brain/pathology , Cognition , Schizophrenia , Schizophrenic Psychology , Animals , Disease Models, Animal , Humans , International Agencies , Schizophrenia/diagnosis , Schizophrenia/genetics , Schizophrenia/pathology , Schizophrenia/therapy , Societies, Scientific
8.
Addict Biol ; 15(4): 448-63, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20731630

ABSTRACT

Recent preclinical evidence indicates that the neuropeptide oxytocin may have potential in the treatment of drug dependence and drug withdrawal. Oxytocin reduces methamphetamine self-administration, conditioned place preference and hyperactivity in rodents. However, it is unclear how oxytocin acts in the brain to produce such effects. The present study examined how patterns of neural activation produced by methamphetamine were modified by co-administered oxytocin. Male Sprague-Dawley rats were pretreated with either 2 mg/kg oxytocin (IP) or saline and then injected with either 2 mg/kg methamphetamine (IP) or saline. After injection, locomotor activity was measured for 80 minutes prior to perfusion. As in previous studies, co-administered oxytocin significantly reduced methamphetamine-induced behaviors. Strikingly, oxytocin significantly reduced methamphetamine-induced Fos expression in two regions of the basal ganglia: the subthalamic nucleus and the nucleus accumbens core. The subthalamic nucleus is of particular interest given emerging evidence for this structure in compulsive, addiction-relevant behaviors. When administered alone, oxytocin increased Fos expression in several regions, most notably in the oxytocin-synthesizing neurons of the supraoptic nucleus and paraventricular nucleus of the hypothalamus. This provides new evidence for central actions of peripheral oxytocin and suggests a self-stimulation effect of exogenous oxytocin on its own hypothalamic circuitry. Overall, these results give further insight into the way in which oxytocin might moderate compulsive behaviors and demonstrate the capacity of peripherally administered oxytocin to induce widespread central effects.


Subject(s)
Amphetamine-Related Disorders/physiopathology , Hypothalamus/drug effects , Methamphetamine/pharmacology , Nucleus Accumbens/drug effects , Oxytocin/pharmacology , Subthalamic Nucleus/drug effects , Animals , Compulsive Behavior/physiopathology , Dopamine/metabolism , Dose-Response Relationship, Drug , Hypothalamus/physiopathology , Male , Motor Activity/drug effects , Motor Activity/physiology , Nerve Net/drug effects , Nerve Net/physiopathology , Neurons/drug effects , Neurons/physiology , Nucleus Accumbens/physiopathology , Oxytocin/metabolism , Paraventricular Hypothalamic Nucleus/drug effects , Paraventricular Hypothalamic Nucleus/physiopathology , Proto-Oncogene Proteins c-fos/metabolism , Rats , Rats, Sprague-Dawley , Stimulation, Chemical , Subthalamic Nucleus/physiopathology , Supraoptic Nucleus/drug effects , Supraoptic Nucleus/physiopathology
9.
Behav Pharmacol ; 20(1): 45-55, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19179850

ABSTRACT

Few studies have investigated the effects of chronic cannabinoid exposure on memory performance and whether tolerance occurs to cannabinoid-induced memory impairment. Here, we studied the effects of repeated exposure to Delta-tetrahydrocannabinol (THC: 1 mg/kg) on spatial memory and zif268 expression in mice. One group of animals was not pretreated with THC, whereas another group was injected with 13 daily injections of THC before memory testing in the Morris water maze. Both groups were administered with THC throughout the memory-testing phase of the experiment. THC decreased spatial memory and reversal learning, even in animals that received the THC pretreatment and were tolerant to the locomotor suppressant effects of the drug. Zif268 immunoreactivity was reduced in the CA3 of the hippocampus and in the prefrontal cortex only in non-pretreated animals, indicating that although tolerance to the effects of THC on neuronal activity was evident, cannabinoid-induced memory impairment in these animals persisted even after 24 days of exposure. This study shows that after extended administration of THC, its spatial memory-impairing effects are resistant to tolerance.


Subject(s)
Dronabinol/pharmacology , Early Growth Response Protein 1/metabolism , Maze Learning/physiology , Memory/drug effects , Spatial Behavior/drug effects , Animals , Dose-Response Relationship, Drug , Dronabinol/administration & dosage , Dronabinol/adverse effects , Drug Tolerance , Hippocampus/drug effects , Hippocampus/metabolism , Male , Maze Learning/drug effects , Memory Disorders/chemically induced , Mice , Mice, Inbred C57BL , Motor Activity/drug effects , Prefrontal Cortex/drug effects , Prefrontal Cortex/metabolism , Reversal Learning/drug effects , Spatial Behavior/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...